MitoImmune Therapeutics Inc. products

MIT-001 is an innovative clinical candidate that blocks the root cause of graft-versus-host disease, which often occurs during allogenic hematopoietic stem cell transplantation (HSCT), through a mechanism of action that is differentiated from any current treatment.

MIT-001 is expected to meet the medical need for oral mucositis for which there is no cure. It aims to be a first-in-class drug that can be used by both patients with head and neck cancer or hematological cancer with a high incidence and severity of oral mucositis as a side effect of chemoradiation therapy.

Hepatic fibrosis is pre-stage of hepatocirrhosis; High unmet demand for interruption of liver fibrosis.